You just read:

Results on Efficacy of PMZ-1620, an Endothelin-B Agonist, from Ongoing Phase II Trial in Patients with Cerebral Ischemic Stroke Presented at International Stroke Conference 2019

News provided by

Pharmazz, Inc.

Feb 07, 2019, 07:00 ET